The EFFECT notice confirms the IPO is live. Expect pricing within 1-2 trading days and first-day trading shortly after. The pre-revenue status and going concern warning make this a high-risk, high-upside event; watch for the final IPO price relative to the range and any insider lockup terms in the final prospectus.
Price Chart
Executive Summary
Scribe Therapeutics' S-1 registration statement for its IPO was declared effective by the SEC on July 23, 2026. This clears the final regulatory hurdle for the company to price and list its common stock on Nasdaq under the ticker SCTX, with the offering expected to proceed imminently. The IPO is a critical capital event for this pre-revenue, clinical-stage CRISPR biotech, which has a going concern warning from its auditor and is offering 7,150,000 shares at an estimated $13-$15 range alongside a $7.5M private placement by Sanofi.
Key Facts
- SEC declared Scribe Therapeutics' S-1 registration statement (File No. 333-297246) effective on July 23, 2026.
- The IPO is for 7,150,000 shares of common stock at an estimated $13-$15 range, with a concurrent $7.5M private placement by Sanofi.
- The company has applied to list on Nasdaq under the ticker SCTX.
- Scribe is a pre-revenue clinical-stage CRISPR biotech with a going concern warning from its auditor.
- The cross-filing context confirms this is an IPO going effective, not a shelf registration.
Financial Impact
IPO targeting ~$96.2M in net proceeds (midpoint) from 7.15M shares at $13-$15 range plus $7.5M private placement
Risk Factors
- Pre-revenue clinical-stage company with no approved products and substantial doubt about going concern
- IPO pricing and aftermarket performance depend on market appetite for speculative biotech IPOs
- Dilution from 7.15M new shares plus potential overallotment
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002417 |
| Document: 9999999995-26-002417-index.html | 9999999995-26-002417 |
| Document: 9999999995-26-002417.txt | 9999999995-26-002417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.96 (−48.20%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.96 (−48.20%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.96 (−21.76%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.96 (−21.76%) |
Jul 28, 2026 13w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.96 (−13.07%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.96 (−15.87%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.96 (−26.28%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.96 (−26.28%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers